• Georg Schlachtenberger, Fabian Doerr, Hruy Menghesha, Patrick Lauinger, Philipp Wolber, Anton Sabashnikov, Aron-Frederik Popov, Sascha Macherey-Meyer, Gerardus Bennink, Jens P Klussmann, Thorsten Wahlers, Khosro Hekmat, and Mathias B Heldwein.
• Department of Cardiothoracic Surgery, Heart Center, University Hospital Cologne Kerpener Strasse 62, 50937 Cologne, Germany.
• Medicina (Kaunas). 2022 Jul 27; 58 (8).

AbstractBackground and Objectives: The incidence of distant metastases in patients with head and neck cancer (HNC) is approximately 10%. Pulmonary metastases are the most frequent distant location, with an incidence of 70-85%. The standard treatment options are chemo-, immuno- and radiotherapy. Despite a benefit for long-term survival for patients with isolated pulmonary metastases, pulmonary metastasectomy (PM) is not the treatment of choice. Furthermore, many otorhinolaryngologists are not sufficiently familiar with the concept of PM. This work reviews the recent studies of pulmonary metastatic HNC and the results after pulmonary metastasectomy. Materials and Methods: PubMed, Medline, Embase, and the Cochrane library were checked for the case series' of patients undergoing metastasectomy with pulmonary metastases published since 1 January 2000. Results: We included the data of 15 studies of patients undergoing PM. The 5-year survival rates varied from 21% to 59%, with median survival from 10 to 77 months after PM. We could not identify one specific prognostic factor for long-term survival after surgery. However, at least most studies stated that PM should be planned if a complete (R0) resection is possible. Conclusions: PM showed reliable results and is supposedly the treatment of choice for patients with isolated pulmonary metastases. Patients not suitable for surgery may benefit from other non-surgical therapy. Every HNC patient with pulmonary metastases should be discussed in the multidisciplinary tumor board to optimize the therapy and the outcome.

14 keywords...

hide…